No-spa 40mg tab 24 pc

$2.20

No-spa 40mg tab 24 pc

Quantity:

Description

Composition
Active substance:
1 tablet contains: drotaverine hydrochloride – 40 mg ;.
Excipients:
Magnesium stearate – 3 mg Talcum – 4 mg Povidone – 6 mg corn starch – 35 mg, lactose monohydrate – 52 mg.
Description:
Round biconvex tablets with a greenish yellow or orangish tinge of color, engraved on one side of the spa.
Product form:
Tablets of 40 mg.
At 6, 10, 12, 20 or 24 tablets in blister PVC / Aluminum.
1, 2, 4 or 5 blisters of 6 tablets with instructions for use in a cardboard box.
3 blisters with 10 tablets with instructions for use in a cardboard box.
2 blisters on 12 tablets with instructions for use in a cardboard box.
1 blister 20 or 24 tablets with instructions for use in a cardboard box.
10 tablets in blister Aluminum / Aluminum (laminated resin).
2 blisters with instructions for use in a cardboard box.
60 tablets in a bottle made of polypropylene with a polyethylene stopper, provided with a single-piece dispenser.
1 bottle with instructions for use in a cardboard box.
100 tablets in a bottle made of polypropylene with a polyethylene cap.
1 bottle with instructions for use in a cardboard box.
Contraindications
Hypersensitivity to the active agent or any of the excipients of the drug. Severe hepatic or renal failure. Severe heart failure (low cardiac output syndrome). Children up to age 6 years. Lactation (no clinical data). Hereditary galactose intolerance, lactase deficiency and malabsorption syndrome glucose-galactose (due to the presence in the composition of the lactose monohydrate formulation).
Carefully
If hypotension. In children (lack of clinical application experience). Pregnant women (see. Section “Pregnancy and breast vskrmlivaniya”).
Dosage
40 mg
Indications
Spasms of smooth muscle in diseases of the biliary tract: cholecystolithiasis, cholangiolithiasis, cholecystitis, pericholecystitis, cholangitis, papillitis. Spasms of smooth muscles of the urinary tract: nephrolithiasis, uretrolitiaz, pyelitis, cystitis, bladder spasms.
As adjunctive therapy: spasm of smooth muscles of the gastrointestinal tract: stomach ulcer and duodenal ulcer, gastritis, spasms of cardia and pylorus, enteritis, colitis, irritable bowel syndrome with constipation, irritable bowel syndrome with bloating. Headaches stress. When dysmenorrhoea (menstrual pain).
Interaction with other drugs
Since levodopa: Phosphodiesterase inhibitors, like papaverine, reduce the antiparkinsonian action of levodopa. In appointing Drotaverinum together with levodopa may increase rigidity and tremor.
On the other antispasmodics, including m-holinoblokatory: mutual enhancement antispasmodic action.
Formulations significantly bind to plasma proteins (80%): drotaverin significantly bind to plasma proteins, mainly albumin, gamma and beta globulins (see “Pharmacokinetics”.). No data on the interaction of drotaverine with drugs significantly bind to plasma proteins, but there is a hypothetical possibility of their interaction with the drotaverine-level communication with the protein (the displacement of one of the drugs other of the linkages to the protein and increase in blood free fraction of drug concentration with less strong bond with protein), which hypothetically could increase the risk of pharmacodynamic and / or toxic side effects of this drug.
Overdose
Data on overdose of the drug available. In case of overdose, patients should be under medical supervision, and if necessary, they should be carried out is symptomatic and aimed at maintaining the basic functions of the body treatment, including artificial induction of vomiting or gastric lavage.
pharmachologic effect
Pharmacological group:
Antispasmodic.
Pharmacodynamics:
Drotaverine represents isoquinoline derivative which exhibits potent antispasmodic effect on smooth muscle by inhibiting the enzyme phosphodiesterase type IV (PDE IV). Enzyme inhibition of PDE IV leads to an increase in cAMP concentration, inactivation of myosin light chain kinase, which further causes relaxation of smooth muscles. Reducing the concentration of Ca2 + ions the effect of drotaverine over cAMP explains drotaverine antagonistic effect with respect to the ions Ca2 +. In vitro drotaverin inhibits PDE IV enzyme without enzyme inhibition of PDE III and PDE V. Therefore drotaverine efficiency depends on PDE IV concentrations in different tissues. PDE IV is most important to inhibit the contractile activity of smooth muscle, and therefore the selective inhibition of PDE IV can be useful for the treatment of hyperkinetic dyskinesias and various diseases accompanied by spastic condition of the gastrointestinal tract. Hydrolysis of cAMP in the myocardium and vascular smooth muscle occurs mainly via the enzyme PDE III, which explains the fact that at high spasmolytic activity in drotaverine no serious side effects of the heart and blood vessels and marked effects on the cardiovascular system. Drotaverinum effective in spasms of smooth muscles of both neurogenic and muscular origin. Regardless of the type of autonomic innervation, Drotaverinum relaxes the smooth muscles of the gastrointestinal tract, biliary tract, urogenital system. Due to its vasodilating action Drotaverinum improves blood circulation. Thus, the above described mechanisms of action Drotaverinum eliminate the spasm of smooth muscles, which leads to a decrease in pain.
Pharmacokinetics:
Absorption: in comparison with papaverine Drotaverinum when administered more quickly and more completely absorbed from the gastrointestinal tract. After the first pass metabolism in the systemic circulation flows 65% of the dose of drotaverine. The maximum concentration (Cmax) drotaverine plasma levels achieved after 45-60 minutes.
Distribution: In vitro drotaverin has a high bond to plasma proteins (95-98%), especially with albumin, gamma and beta globulins. Drotaverinum evenly distributed in tissues, penetrates into the smooth muscle cells. It does not cross the blood-brain barrier. Drotaverine and / or its metabolites can slightly penetrate the placenta.
Metabolism: Drotaverinum almost completely metabolized in the liver.
Excretion: drotaverine half-life is 8-10 hours. Within 72 hours drotaverin almost completely excreted. About 50% of Drotaverinum excreted by the kidneys and about 30% – through the gastrointestinal tract. Drotaverine excreted mainly as metabolites, drotaverine unmodified form can not be detected in the urine.
Pregnancy and breast-feeding
Our studies revealed no teratogenic and embryotoxic action Drotaverinum, as well as adverse effects on pregnancy. However, if necessary, the drug-shpa® But during pregnancy, caution should be exercised, and prescribed the drug only after the evaluation of the ratio of potential benefits to the mother and the potential risk to the fetus. Due to the lack of animal studies and clinical data, assign Drotaverinum during breastfeeding is not recommended.
Conditions of supply of pharmacies
Without recipe.
side effects
Below are adverse reactions observed in clinical trials, separated by organ systems indicating the frequency of their occurrence according to the following gradation: very frequent (> 10%), frequent (> 1%,
special instructions
But-shpa® tablets 40 mg containing 52 mg of lactose. It can cause gastrointestinal complaints in individuals suffering from lactose intolerance. This form is unacceptable for patients suffering from lactose deficiency, galactosemia syndrome or disturbed absorption of glucose / galactose (see. The section “Contra ‘).
Effects on ability to drive and use other mechanisms
When administered in therapeutic doses of drotaverin did not affect the ability to drive and do work requiring attention. If you notice any side effects a question about driving vehicles and using machinery requires individual consideration. In the event of dizziness after taking the drug, you should avoid activities potentially hazardous activities such as driving and operating machinery.
Storage conditions
For tablets in blisters Aluminum / Aluminum: stored at a temperature not higher than 30 C.
For tablets in blisters of PVC / Aluminum: stored at a temperature not higher than 25 C.
Pill in vials: store in the dark place at a temperature of 15 C to 25 C.
Keep out of the reach of children.
Dosing and Administration
Adults: 1-2 tablets at a time 2-3 times a day. The maximum daily dose – 6 tablets (corresponding to 240 mg).
Children: clinical studies on the use of Drotaverinum not been conducted in children. In the case of the appointment of Drotaverinum children – from 6 to 12 years: 1 tablet per reception 1-2 times a day. The maximum daily dose – 2 tablets (corresponding to 80 mg); – over 12 years: 1 tablet per reception 1-4 times a day or 2 tablets at a time 1-2 times a day. The maximum daily dose – 4 tablets (corresponding to 160 mg). Before the drug without consulting a doctor recommended duration of administration of the drug is typically 1-2 days. In cases where drotaverin applied as an adjuvant therapy, duration of treatment without consultation with a physician may be greater (2-3 days). If the pain persists, the patient should see a doctor.
When using a vial with a plastic stopper, provided with a dispenser MMA: before use to remove the protective strip from the top of the bottle and the label from the bottom of the vial. Place the vial in the palm so that the dispensing opening on the bottom is not rested on the palm. Then pressure on the upper part of the bottle, whereby one tablet to fall out of the dispensing opening on the bottom.
Method of evaluating the effectiveness if the patient can easily self-diagnose the symptoms of the disease, as they are for it is well known, the effectiveness of the treatment, namely the disappearance of pain, and the patient can be easily evaluated. If within a few hours after taking the maximum single dose there is a moderate decrease in pain or not pain relief, or if the pain is significantly reduced after taking the maximum daily dose, it is recommended to consult a doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

SANOFI AVENTIS GROUP

There are no reviews yet.

Add your review